1. Consensus Development Conference: Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993; 94:646-50.
2. World Health Organization; Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical Report Series 843. World Health Organization Geneva, Switzerland, 1994.
3. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Br Med J 1996; 312:1254-9.
4. Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. Lancet 1993; 341:72-5.
5. Kanis JA & the WHO Study Group Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Synopsis of a WHO Report. Osteoporos Int 1994; 4:368-81.
6. Goulding A, Jones IE, Taylor RW, et al. More broken bones: a 4-year double cohort study of young girls with and without distal forearm fractures. J Bone Miner Res 2000; 15:2011-8.
7. Skaggs DL, Loro ML, Pitukcheewanont P, et al. Increased body weight and decreased radial cross-sectional dimension in girls with forearm fractures. J Bone Miner Res 2001; 16:1337-42.
8. Ward LM, Glorieux FH. The spectrum of pediatric osteoporosis. In: Glorieux FH, Pettifor JM, Jüppner H eds. Pediatric Bone: Biology & Diseases. Amsterdam: Academic Press, 2003; 401-42.
9. Robson H, Siebler T, Stevens DA. Thyroid hormone acts directly on growth plate chondrocyte to promote hypertrophic differentiation and inhibit clonal expansion and cell proliferation. Endocrinology 2000; 141:3887-97.
10. Trotter M, Hixonw BB. Sequential changes in weight, density, and percentage ash weight of human skeleton from an early fetal period through old age. Anat Rec 1974; 179:1-18.
11. Bonjour JP, Theintz G, Buchs B, et al. Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. J Clin Endocrinol Metab 1991; 73:555-63.
12. Sabatier JP, Guaydier-Souquieres G, Laroche D, et al. Bone mineral acquisition during adolescence and early adulthood: a study in 574 healthy females 10-24 years of age. Osteoporos Int 1996; 6(2):141-8.
13. Lazcano-Ponce E, Tamayo J, Cruz-Valdez A, et al. Peak bone mineral area density and determinants among females aged 9 to 24 years in Mexico. Osteoporos Int 2003; 14(7):539-47.
14. Lu PW, Briody JN, Ogle GD, et al. Bone mineral density of total body, spine and femoral neck in children and young adults: a cross-sectional and longitudinal study. J Bone Miner Res 1994; 9:1451-8.
15. Gilsanz V, Kovanlikaya A, Costin G, et al. Differential effect of gender on the size of the bones in the axial and appendicular skeleton. J Clin Endocrinol Metab 1997; 82:1603-7.
16. Peacock M, Turner CH, Econs MJ, et al. Genetics of osteoporosis, Endocr Rev 2002; 23:303-26.
17. Morris FL, Payne WR, Wark JD. The impact of intense training on endogenous estrogen and progesterone concentrations and bone mineral acquisition in adolescent rowers. Osteoporos Int 1999; 10:361-8.
18. Cheng JC, Maffulli N, Leung SS, et al. Axial and peripheral bone mineral acquisition: A 3-year longitudinal study in Chinese adolescents. Eur J Pediatr 1999; 158:506-12.
19. Johnston CC, Miller JZ, Slemenda CW, et al. Calcium supplementation and increases in bone mineral density in children. N Engl J Med 1992; 327: 82-87.
20. Dent CE, Friedman M. Idiopathic juvenile osteoporosis. Quart J Med 1965; 34: 177-210.
21. Teotia M, Teotia SP, Singh RK. Idiopathic juvenile osteoporosis. Am J Dis Child 1979; 133:894-900.
22. Smith R. Idiopathic juvenile osteoporosis: experience of twenty-one patients. J Rheumatol 1995; 34:68-77.
23. Rauch F, Traves R, Norman ME, et al. The bone formation defect in idiopathic juvenile osteoporosis is surface-specific. Bone 2002; 31:85-9.
24. Cimaz R, Falcini F. Skeletal maturation and bone mineralization in the pediatric rheumatic diseases. In: Cassidy JT, Petty RP, eds. Textbook of Pediatric Rheumatology. 5th ed. Philadelphia, PA: Elsevier, 2005; 716-27.
25. Henderson CJ, Cawkwell GD, Specker BL, et al. Predictors of total body bone mineral density in non-corticosteroid-treated prepubertal children with juvenile rheumatoid arthritis. Arthritis Rheum 1997; 40:1967-75.
26. Henderson CJ, Specker BL, Sierra RI, et al. Total-body bone mineral content in non-corticosteroid-treated postpubertal females with juvenile rheumatoid arthritis. Frequency of osteopenia and contributing factors. Arthritis Rheum 2000; 43:531-40.
27. Zak M, Hassager C, Lovell DJY. Assessment of bone mineral density in adults with a history of juvenile chronic arthritis: a cross sectional long-term follow-up study. Arthritis Rheum 1999; 42:790-8.
28. Haugen M, Lien G, Flato B, et al. Young adults with juvenile arthritis in remission attain normal peak bone mass at the lumbar spine and forearm. Arthritis Rheum 2000; 43:1504-10.
29. French AR, Mason T, Nelson AM, et al. Osteopenia in adults with a history of juvenile rheumatoid arthritis. A population based study. J Rheumatol 2002; 29: 1065-70.
30. Chesney RW, Mazess RB, Rose, P, et al. Effect of prednisone on growth and bone mineral content in childhood glomerular disease. Am J Dis Child 1987; 132:768-72.
31. Naganathan V, Jones G, Nash P, et al. Vertebral fracture risk with long-term corticosteroid therapy: prevalence and relation to age, bone density, and corticosteroid use. Arch Intern Med 2000; 160:2917-22.
32. Bardare M, Bianchi ML, Furia M, et al. Bone mineral metabolism in chronic arthritis: the influence of steroids. Clin Exp Rheumatol 1991; 9(Suppl. 6):29-31.
33. Jones G, Ponsonby AL, Smith BJ, et al. Asthma, inhaled corticosteroid use, and bone mass in prepubertal children. J Asthma 2000; 37:603-11.
34. Sievanen H, Oja P, Vuori I. Precision of dual-energy X-ray absorptiometry in determining bone mineral density and content in various skeletal sites. J Nucl Med 1992; 33:1137-42.
35. Njeh CF, Samat SB, Nightingale A, et al. Radiation dose and in vivo precision in paediatric bone mineral density measurement using dual X-ray absorptio-metry. Br J Radiol 1997; 70:719-27.
36. Koo WW, Walters J, Bush AJ, Technical consideration of dual-energy X-ray absorptiometry-based bone mineral measurements for pediatric subjects. J Bone Miner Res 1995; 10:1998-2004.
37. Warner JT, Cowan FJ, Dunstan FDJ, et al. Measured and predicted bone mineral content in healthy boys and girls aged 6-18 years: adjustment for body size and puberty. Acta Paediatr 1998; 87:244-9.
38. Rauch F, Tutlewski B, Fricke O, et al. Analysis of cancellous bone turnover by multiple slice analysis at distal radius: a study using peripheral quantitative computed tomography. J Clin Densitom 2001; 4:257-62.
39. Lewiecki EM, Watts NB, McClung MR, et al. Official positions of the International Society for Clinical Densitometry. J Clin Endocrinol Metab 2004; 89:3651-5.
40. McGartland C, Robson P, Murray L, et al. History of fracture and bone mineral density in adolescence: The N. Ireland young hearts project. Bone. 2005; 36(Suppl. 1):S39.
41. Szulc P, Seeman E, Delmas P. Biochemical measurements of bone turnover in children and adolescents. Osteoporos Int 2000; 11:281-294.
42. Tylavsky FA, Holliday K, Danish R, et al. Fruit and vegetables intake is an independent predictor of bone size in early-pubertal children. Am J Clin Nutr 2004; 79:311-7.
43. Brown SJ, Schoenly L. Test of an educational intervention for osteoporosis prevention with U.S. adolescents. Orthopaedic Nursing 2004; 23(4):245-51.
44. Ginty F, Prentice A. Can osteoporosis be prevented with dietary strategies during adolescence? Br J Nutr 2004; 92(1):5-6.
45. Henderson CJ, Lovell DJ. Nutritional aspects of juvenile rheumatoid arthritis. Rheum Dis Clin North Am 1991; 17:403-13.
46. Bonjour JP, Carrie AL, Ferrari S, et al. Calcium-enriched food and bone mass growth in prepubertal girls: a randomized, double-blind, placebo-controlled trial. J Clin Invest 1997; 99:1287-94.
47. Whiting SJ, Vatanparast H, Baxter-Jones A, et al. Factors that affect bone mineral accrual in the adolescent growth spurt. J Nutr 2004; 134:696S-700S.
48. McGartland C, Robson PJ, Murray L, et al. Carbonated soft drink consumption and bone mineral density in adolescence: the Northern Ireland young hearts project. J Bone Miner Res 2003; 18:1563-9.
49. Kalkwarf HJ, Khoury JC, Lanphear BP. Milk intake during childhood and adolescence, adult bone density, and osteoporotic fractures in US women. Am J Clin Nutr 2003; 77:257-65.
50. Crocombe S, Berry JL, Mughal MZ. Symptomatic vitamin D deficiency among non-Caucasian adolescents living in the United Kingdom. Arch Dis Child 2004; 89:197-9.
51. Whalen RT, Carter DR. Influence of physical activity on the regulation of bone density. J Biomech 1988; 21:825-37.
52. Slemenda WC, Miller JZ, Hui SL, et al. Role of physical activity in the development of skeletal mass in children. J Bone Miner Res 1991; 6:1227-33.
53. Warady BD, Lindsley CB, Robinson FG, et al. Effects of nutritional supplementations on bone mineral status of children with rheumatic diseases receiving corticosteroids. J Rheumatol 2004; 21:530-5.
54. Reed A, Haugen M, Patchman LM, et al. 25-hydroxyvitamin D therapy in children with active juvenile rheumatoid arthritis: short-term effects on serum osteocalcin levels and bone mineral density. J Pediatr 1991; 119:657-60.
55. Bianchi ML, Bardare M, Galbiati E. Bone development in juvenile rheumatoid arthritis. In: Schonau E, Matkovic V, eds. Paediatric Osteology, Prevention of Osteoporosis - A Paediatric Task ?: Singapore: Elsevier Science, 1998:173-81.
56. Brumsen C, Hamdy NA, Papopoulos SE. Long-term effects of bispho-sphonates on the growing skeleton: studies of young patients with severe osteoporosis. Medicine (Baltimore). 1997; 76:266-83.
57. Van Persijn, Van Meerten EL, Kroon HM, et al. Epi- and metaphyseal changes in children causes by administration of bisphosphonates. Radiology 1992; 184: 249-54.
58. Shoemaker LR. Expanding role of bisphosphonate therapy in children. J Pediatr 1999; 134:264-7.
59. Srivastava T, Alon US. Bisphosphonates: from grandparents to grandchildren. Clin Pediatr 1999; 38:687-702.
60. Shaw NJ, Boivin CM, Crabtree NJ. Intravenous pamidronate in juvenile osteoporosis. Arch Dis Child 2000; 83:143-5.
61. Falcini F, Trapani S, Ermini M, et al. Intravenous administration of alendronate counteracts the in vivo effects of glucocorticoids on bone remodelling. Calcified Tissue Int 1996; 58:166-9.
62. Lepore L, Pennesi M, Barbi E, et al. Treatment and prevention of osteoporosis in juvenile chronic arthritis with disodium clodronate. Clin Exp Rheumatol 1991; 9(Suppl. 6):33-5.
63. Noguera A, Ros JB, Pavia C, et al. Bisphosphonates, a new treatment for glucocorticoid-induced osteoporosis in children. J Pediatr Endocrinol 2003; 16: 529-36.
64. Bianchi ML, Cimaz R, Bardare M, et al. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children. Arthritis Rheum 2000; 43:1960-6.
65. Cimaz R, Gattorno M, Sormani MP, et al. Changes in markers of bone turnover and inflammatory parameters during alendronate therapy in pediatric patients with rheumatic disease. J Rheumatol 2002; 29:1786-92.
66. Whyte MP, Wenkert D, Clements KL, et al. Bisphosphonate-induced osteopetrosis. N Engl J Med 2003; 349:457-63.
67. Simon D, Prewar A, Czernichow P. Treatment of juvenile rheumatoid arthritis with growth hormone. Horm Res 2000; 53:82-6.
68. Touati G, Ruiz JC, Porquet D, et al. Effects on bone metabolism of one year recombinant human growth hormone administration to children with juvenile chronic arthritis undergoing chronic steroid therapy. J Rheumatol 2000; 27: 1287-93.
69. Bechtold S, Ripperger P, Bonfig W, et al. Bone mass development and bone metabolism in juvenile idiopathic arthritis: treatment with growth hormone for 4 years. J Rheumatol 2004; 31:1407-12.
70. Rooney M, Davies UM, Reeve J, et al. Bone mineral content and bone mineral metabolism: changes after growth hormone treatment in juvenile chronic arthritis. J Rheumatol 2000; 27:1073-81.
71. Simon D, Lucidarme N, Prieur AM, et al. Effects on growth and body composition of growth hormone treatment in children with juvenile idiopathic arthritis requiring steroid therapy. J Rheumatol 2003; 30:2492-9.
72. Siamopoulou A, Challa A, Kapoglou P, et al. Effects of intranasal salmon calcitonin in juvenile idiopathic arthritis: an observational study. Calcified Tissue Int 2001; 69:25-30.
73. Neer RM, Arnaud CD, Zanchetta JR, et al. Recombinant human PTH (1-34) fragment [rh-PTH] reduces the risk of spine and non-spine fractures in postmenopausal osteoporosis. N Engl J Med 2001; 344:1434-41.
74. Quattrocchi E, Kourlas H. Teriparatide: a review. Clin Ther 2004; 26:841-54.
Was this article helpful?
Thank you for deciding to learn more about the disorder, Osteoarthritis. Inside these pages, you will learn what it is, who is most at risk for developing it, what causes it, and some treatment plans to help those that do have it feel better. While there is no definitive “cure” for Osteoarthritis, there are ways in which individuals can improve their quality of life and change the discomfort level to one that can be tolerated on a daily basis.